Academic Journal of Second Military Medical University (第二军医大学学报) 2011/31:9 PP.974-978
Objective To study the positive rate of PF4/H antibodies in maintenance hemodialysis patients, and to analyze its risk factor and association with thrombosis. Methods A total of 157 maintenance hemodialysis patients were recruited in the present study. A cross-sectional and a longitude study were designed, and statistical analysis was used to analyze the risk factors of PF4/H antibody level and its association with thrombosis event. Results We found that 40.8%(64/157) of the patients were positive for PF4/H antibody. Past-thrombosis events, heparin types, duration and weekly dialysis hours were significantly different between antibody-positive group and antibody-negative group(P<0.05). Incidence of thrombosis event in antibody-positive group was significantly lower than that in the antibody-negative group(P<0.05). The risk ratio of antibody positivity for thrombosis event was 2.349. The incidence of thrombotic event in antibody-positive patients who took anti-platelet agents was lower than that in those who did not take. Conclusion The positive rate of PF4/H antibody has been found to be 40.8% in the present group. Thrombosis events, heparin types, duration and weekly dialysis hours are the risk factors of PF4/H antibody level. PF4/H antibody can serve as a marker for thrombotic events, and anti-platelet agents are effective for preventing from thrombotic events in PF4/H antibody positive patients.
Funds：Fund of “Eleventh Five-Year-Plan” of PLA Medical Research (08Z034)
 Greinacher A,Althaus K,Krauel K,Selleng S.Heparin-induced thrombocytopenia[J].Hamostaseologie,2010,30:17-18,20-28.
 Chang J J,Parikh C R.When heparin causes thrombosis: significance,recognition,and management of heparin-induced thrombocytopenia in dialysis patients[J].Semin Dial,2006,19:297-304.
 Mattioli A V,Bonetti L,Zennaro M,Ambrosio G,Mattioli G.Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up[J].Am Heart J,2009,157:589-595.
 Mattioli A V,Bonetti L,Carletti U,Ambrosio G,Mattioli G.Thrombotic events in patients with antiplatelet factor 4/heparin antibodies[J].Heart,2009,95:1350-1354.
 Benjamin J,Moldavsky S,Lee J,Rubin R.Prevalence of heparin-induced antibody in African-American hemodialysis patients-comparison to non-dialysis patients[J].Clin Nephrol,2009,71:263-266.
 Warkentin T E,Sheppard J A,Sigouin C S,Kohlmann T,Eichler P,Greinacher A.Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia[J].Blood,2006,108:2937-2941.
 Warkentin T E,Sheppard J A,Horsewood P,Simpson P J,Moore J C,Kelton J G.Impact of the patient population on the risk for heparin-induced thrombocytopenia[J].Blood,2000,96:1703-1708.
 Selleng S,Malowsky B,Itterman T,Bagemühl J,Wessel A,Wollert H G,et al.Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery[J].Am Heart J,2010,160:362-369.
 Warkentin T E,Levine M N,Hirsh J,Horsewood P,Roberts R S,Gent M,et al.Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin[J].N Engl J Med,1995,332:1330-1335.
 Martel N,Lee J,Wells P S.Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis[J].Blood,2005,106:2710-2715.
 Matsuo T,Kobayashi H,Matsuo M,Wanaka K,Nakamoto H,Matsushima H,et al.Frequency of anti-heparin-PF4 complex antibodies(HIT antibodies) in uremic patients on chronic intermittent hemodialysis[J].Pathophysiol Haemost Thromb,2006,35:445-450.
 Carrier M,Knoll G A,Kovacs M J,Moore J C,Fergusson D,Rodger M A.The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis[J].Thromb Res,2007,120:215-220.
 Adiguzel C,Bansal V,Litinas E,Cunanan J,Iqbal O,Nelson K,et al.Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin[J].Clin Appl Thromb Hemost,2009,15:145-151.
 Dixon B S,Beck G J,Vazquez M A,Greenberg A,Delmez J A,Allon M,et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency[J].N Engl J Med,2009,360:2191-2201.
 Milburn J A,Cassar K,Ford I,Fluck N,Brittenden J.Prothrombotic changes in platelet,endothelial and coagulation function following hemodialysis[J].Int J Artif Organs,2011,34:280-287.
 Chou C Y,Chen J Y,Liu J H,Liu Y L,Lin H H,Yang Y F,et al.Atrial fibrillation linked to vascular access thrombosis in chronic hemodialysis patients[J].J Atheroscler Thromb,2011,18:448-453.
 Gruel Y,Lermusiaux P,Lang M,Darnige L,Rupin A,Delahousse B,et al.Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis[J].Ann Vasc Surg,1991,5:552-555.
 Kappa J R,Fisher C A,Addonizio V P Jr.Heparin-induced platelet activation: the role of thromboxane A2 synthesis and the extent of platelet granule release in two patients[J].J Vasc Surg,1989,9:574-579.
 Warkentin T E.Heparin-induced thrombocytopenia: a clinicopathologic syndrome[J].Thromb Haemost,1999,82:439-447.
 Hach-Wunderle V,Kainer K,Krug B,Müller-Berghaus G,Potzsch B.Heparin-associated thrombosis despite normal platelet counts[J].Lancet,1994,344: 469-470.
 Di Micco B,Colonna G,Di Micco P,Di Micco G,Russo B M,Macalello M A,et al.Anti-thrombin action of low-dose acetylsalicylic acid[J].Eur J Pharmacol,2003,460:59-62.
 Rand M L,Perry D W,Packham M A,Gemmell C H,Yeo E L,Kinlough-Rathbone R L.Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: direct measurement of percent release of beta-thromboglobulin and assessment by flow cytometry of P-selectin expression[J].Am J Hematol,1996,52:288-294.